Comparison·Analysis of Body Composition and Side Effects of Colorectal Cancer Patients by Chemotherapy Treatment Cycle

Background: Late state colorectal cancer treatments have important side effects that should be avoided in patients where drug effectiveness is not adequate. PrediCTC is a new biomarkers blood test developed to determinate the chemotherapy response in unresectable metastatic colorectal cancer patients that could allow to obviate unnecessary treatments. Aim: To assess from the Spanish Societal Perspective the cost-utility of the test PrediCTC compared to the computed tomography in aim to evaluate chemotherapy treatment response in late stage colorectal cancer patients. Methods: Based on the results of Barbazán et al., a Markov model has been developed, in which the different lines and cycles that the colorectal patient can receive and how they can move between them according to the computed tomography or PrediCTC have been represented. The effectiveness has been expressed in quality adjusted life years (QALYs), avoiding adverse events. Results: Base case analysis shows savings in different types of costs for PrediCTC (per patient): €14.30 in those arise from adverse events, €22,345.73 in chemotherapy costs, €4849.61 in other direct costs, and €306.21 in indirect costs. Although computed tomography 12-week assessed patients gain 0.17 QALYs compared with PrediCTC. Conclusions: From the Spanish Societal Perspective, PrediCTC is not a cost-utility option but allows to identify earlier patients who are not benefiting from first-line chemotherapy avoiding unnecessary side effects and costs.

Download Full-text

Barriers to physical activity participation in colorectal cancer patients during chemotherapy treatment: A qualitative study

European Journal of Oncology Nursing ◽

10.1016/j.ejon.2020.101769 ◽

2020 ◽

Vol 46 ◽

pp. 101769 ◽

Cited By ~ 1

Author(s):

María Romero-Elías ◽

Vicente J. Beltrán-Carrillo ◽

David González-Cutre ◽

Alejandro Jiménez-Loaisa

Keyword(s):

Physical Activity ◽

Colorectal Cancer ◽

Qualitative Study ◽

Cancer Patients ◽

Physical Activity Participation ◽

Activity Participation ◽

Chemotherapy Treatment ◽

Colorectal Cancer Patients ◽

Barriers To Physical Activity

Download Full-text

Dihydropyrimidine Dehydrogenase Gene Variation and Its Association with 5-Fluorouracil Toxicity in Colorectal Patients

Asian Pacific Journal of Cancer Biology ◽

10.31557/apjcb.2018.3.3.65 ◽

2018 ◽

Vol 3 (3) ◽

pp. 65-69

Author(s):

Ebrahim Salehifar ◽

Mohammad Javad Abd Haghighi ◽

Reza Negarandeh ◽

Ghasem Janbabai ◽

Fatemeh Safgafi ◽

...

Keyword(s):

Colorectal Cancer ◽

Side Effects ◽

Cancer Patients ◽

Dihydropyrimidine Dehydrogenase ◽

Venous Blood ◽

Critical Role ◽

Optimization Method ◽

Gene Variation ◽

North Of Iran ◽

Colorectal Cancer Patients

Objective: Dihydropyrimidine dehydrogenase (DPD), an enzyme translated by DPD gene (DPYD), has a critical role in the metabolism of 5-fluorouracil (5FU). In this study we aimed to investigate the frequency of the IVS14+1 G>A, 2194G>A, 2846 A>T mutations in the DPYD gene in colorectal cancer patients in north of Iran and their association with side effects of 5FU.Methods: Venous blood samples of 89 colorectal cancer patients were drawn. After the DNA extraction from nuclear cells, a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to detect the frequency of the IVS14+1 G>A and 2846 A>T mutations. Tetra-Primer ARMS PCR optimization method was used to detect the 2194 G>A mutation. Side effects were classified according to CTCAE (common terminology criteria for adverse events V. 4) and the association between different polymorphisms and side effects were evaluated.Results: Of 89 colorectal patients, the frequency of IVS14+1 G>A and 2846 A>T polymorphism was 4 (5.1%) and 1 (1.1%), respectively. The 2194 G>A polymorphism was not detected. All 4 patients were heterozygous for IVS14+1 G>A mutation, whereas the only patient with 2846 A>T polymorphism was homozygous. Some adverse effects of 5FU including diarrhea, vomiting, mucositis and stomatitis were more frequent in patients with IVS14+1 G>A polymorphism.Conclusion: The prevalence of IVS14+1 G>A mutation in our patients were relatively high and was associated with a higher occurrence of 5FU-associated toxicities.

Download Full-text